BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 26802069)

  • 1. Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium - 1997-2006-2016. Part 1.
    Thomsen HS
    Acta Radiol; 2016 May; 57(5):515-20. PubMed ID: 26802069
    [No Abstract]   [Full Text] [Related]  

  • 2. Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium - 1997-2006-2016. Part 2.
    Thomsen HS
    Acta Radiol; 2016 Jun; 57(6):643-8. PubMed ID: 26802070
    [No Abstract]   [Full Text] [Related]  

  • 3. Gadolinium and nephrogenic systemic fibrosis.
    Runge VM
    AJR Am J Roentgenol; 2009 Apr; 192(4):W195-6; discussion W197. PubMed ID: 19304681
    [No Abstract]   [Full Text] [Related]  

  • 4. Pathomechanisms of nephrogenic systemic fibrosis: new insights.
    Gupta A; Shamseddin MK; Khaira A
    Clin Exp Dermatol; 2011 Oct; 36(7):763-8. PubMed ID: 21790732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rehabilitation in nephrogenic systemic fibrosis.
    Ramaizel L; Sliwa JA
    PM R; 2009 Jul; 1(7):684-6. PubMed ID: 19627963
    [No Abstract]   [Full Text] [Related]  

  • 6. Focus on contrast-associated nephrogenic systemic fibrosis.
    Partain CL
    J Magn Reson Imaging; 2009 Dec; 30(6):1231-2. PubMed ID: 19938033
    [No Abstract]   [Full Text] [Related]  

  • 7. Special issue: nephrogenic systemic fibrosis.
    Leiner T; Kucharczyk W
    J Magn Reson Imaging; 2009 Dec; 30(6):1233-5. PubMed ID: 19938034
    [No Abstract]   [Full Text] [Related]  

  • 8. Free gadolinium is a likely trigger of nephrogenic systemic fibrosis.
    Abraham JL; Edward M
    AJR Am J Roentgenol; 2009 Oct; 193(4):W354; author reply W355. PubMed ID: 19770307
    [No Abstract]   [Full Text] [Related]  

  • 9. Nephrogenic systemic fibrosis: is gadolinium to be blamed?
    Jikki PN
    J Assoc Physicians India; 2008 Nov; 56():915-6. PubMed ID: 19263697
    [No Abstract]   [Full Text] [Related]  

  • 10. Nephrogenic systemic fibrosis: possible mechanisms and imaging management strategies.
    Dawson P
    J Magn Reson Imaging; 2008 Oct; 28(4):797-804. PubMed ID: 18821621
    [No Abstract]   [Full Text] [Related]  

  • 11. Correction to the relative risk calculation for gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis.
    Jain R; Levine M
    Radiology; 2010 Apr; 255(1):307-8; author reply 308. PubMed ID: 20308469
    [No Abstract]   [Full Text] [Related]  

  • 12. Nephrogenic systemic fibrosis: the need for accurate case reporting.
    Spinazzi A; Kirchin MA; Pirovano G
    J Magn Reson Imaging; 2009 May; 29(5):1240; author reply 1241. PubMed ID: 19388104
    [No Abstract]   [Full Text] [Related]  

  • 13. Gadolinium and systemic fibrosis: guilt by association.
    Kay J; Czirják L
    Ann Rheum Dis; 2010 Nov; 69(11):1895-7. PubMed ID: 20959325
    [No Abstract]   [Full Text] [Related]  

  • 14. Gadolinium-associated nephrogenic systemic fibrosis in patients with renal failure: the need for an interdisciplinary helping network.
    Stratta P; Canavese C; Quaglia M; Fenoglio R
    Rheumatology (Oxford); 2010 Apr; 49(4):821-3. PubMed ID: 20032228
    [No Abstract]   [Full Text] [Related]  

  • 15. Gadolinium-associated nephrogenic systemic fibrosis.
    Schlaudecker JD; Bernheisel CR
    Am Fam Physician; 2009 Oct; 80(7):711-4. PubMed ID: 19817341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrogenic systemic fibrosis and gadolinium: a cautionary tale in the molecular imaging era.
    Wang SC
    J Med Imaging Radiat Oncol; 2008 Aug; 52(4):305-6. PubMed ID: 18811752
    [No Abstract]   [Full Text] [Related]  

  • 17. Nephrogenic systemic fibrosis and gadolinium-enhanced magnetic resonance imaging: does a US Food and Drug Administration alert influence practice patterns in CKD?
    Martin DR
    Am J Kidney Dis; 2010 Sep; 56(3):427-30. PubMed ID: 20728788
    [No Abstract]   [Full Text] [Related]  

  • 18. Nephrogenic systemic fibrosis developed after recovery from acute renal failure: gadolinium as a possible aetiological factor.
    Lu CF; Hsiao CH; Tjiu JW
    J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):339-40. PubMed ID: 18573157
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety of magnetic resonance contrast media: a review with special focus on nephrogenic systemic fibrosis.
    Haneder S; Kucharczyk W; Schoenberg SO; Michaely HJ
    Top Magn Reson Imaging; 2015 Feb; 24(1):57-65. PubMed ID: 25654421
    [No Abstract]   [Full Text] [Related]  

  • 20. Contemporary applications and limitations of magnetic resonance imaging contrast materials.
    Natalin RA; Prince MR; Grossman ME; Silvers D; Landman J
    J Urol; 2010 Jan; 183(1):27-33. PubMed ID: 19913804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.